Rejuvenate Bio

[Rejuvenate Bio @rejuvenatebio]

Excited to share our paper in @CellRepJrnl co-authored by our CSO @eskamoah which shows extension of median remaining lifespan in extremely old wild-type mice accompanied by improved health outcomes via systemic AAV-based partial reprogramming therapy: 🧬

https://t.co/9MwbabM1UE

[Rejuvenate Bio @rejuvenatebio]

Our CEO @DanielCOliver was at @LSXLeaders in Boston on the Commercialization Strategies for Biotechs and Early Planning panel. Thanks for joining us and see you at the next event! 🧬🧬

[Rejuvenate Bio @rejuvenatebio]

Bioprocess International speaks with our CEO @DanielCOliver about the $4M @CIRMnews grant: 🧬🧬

https://t.co/81Ucd7kKQT

[Longevity Technology @LongevityTech]

Rejuvenate Bio lands $4m grant to develop gene therapy with longevity potential
CIRM funding will support the company through IND-enabling studies of FGF21-boosting gene therapy for genetic heart condition.
#longevity #funding #genetherapy
https://t.co/M8BKEvpZXE

[Latest News from Business Wire @NewsFromBW]

Rejuvenate Bio Receives $4M in Funding from the California Institute for Regenerative Medicine (CIRM) https://t.co/2wJqy76JNe

[Rejuvenate Bio @rejuvenatebio]

Excited to announce we received $4M in funding from @CIRMnews to develop our gene therapy RJB-0402 for the treatment of desmoplakin gene variant arrhythmogenic cardiomyopathy.

Read the release:

https://t.co/RX6CDcQ0W0

[BiotechTV @BiotechTV]

BIO 2024: The CEO of @rejuvenatebio on the company's liver directed gene therapy program targeting FGF21. #BIO2024

Full video: https://t.co/c1DeBnZKnc

[Rejuvenate Bio @rejuvenatebio]

We’re excited to present at @ASGCTherapy 2024 on our RJB-0402 gene therapy which targets key disease-mediating pathways in arrhythmogenic cardiomyopathy (ACM). 🧬🧬

Read the release:

https://t.co/gs56bVK4oI

[Noah @eskamoah]

https://t.co/LdbEbhYzlb thanks @WiredMiddleEast for sharing the work we are doing @rejuvenatebio

[Longevity Technology @LongevityTech]

Rejuvenate Bio shows epigenetic reprogramming extends #lifespan in normal mice
New paper first to show that gene therapy-mediated partial #reprogramming extends lifespan and reverses age-related changes in aged wild mice.
@rejuvenatebio #longevity
https://t.co/N89CzEQFAy

[Wyss Institute @wyssinstitute]

Exciting developments from Wyss startup @rejuvenatebio!

[Noah @eskamoah]

New paper out from @rejuvenatebio Congrats to everyone who contributed! @cc_biology_ @Y_Ryan_Lu @LouisMetzger_ https://t.co/6xxw7bxqxR
https://t.co/l0tQKDEt1N

[LEAP @LEAPandInnovate]

How long would you like to live?

Or more importantly, how long would you like to feel healthy, energetic, and able to make the most of your life?

This week, we interviewed Noah Davidsohn (Chief Scientific Officer and Co-founder at Rejuvenate Bio) – an innovator in epigenetics who’s dedicated to helping humans live longer, healthier lives.

Find out how the manipulation of gene expression through epigenetics could transform the way we approach health and medicine. Read the blog here: https://t.co/sRIdqMokB3

#LEAP24 #healthtech #medicine #innovation

[Cellular Reprogramming @CellRepJrnl]

Our new article reveals that gene therapy-mediated partial reprogramming extends lifespan and reverses age-related changes in aged mice, showcasing lifespan extension in wild-type animals through in vivo reprogramming. @eskamoah @cc_biology_ @rejuvenatebio
https://t.co/2WX5kSrW5a

[Longevity Technology @LongevityTech]

Rejuvenate Bio makes progress on osteoarthritis gene therapy for dogs
Gene therapy company inks strategic partnership with animal health firm to develop ‘one-dose’ injection treatment for canine #osteoarthritis.
@rejuvenatebio #longevity #doghealth
https://t.co/761MSOCP3c

[Latest News from Business Wire @NewsFromBW]

Rejuvenate Bio Announces Partnership with Leading Animal Health Company to Develop Gene Therapy for Canine Osteoarthritis https://t.co/YDSjSZu8dv

[Rejuvenate Bio @rejuvenatebio]

Join our CEO @DanielCOliver at #JPM24 #BiotechShowcase24 on Tuesday Jan 9 for this #Cell and #Gene Therapy panel. 🧬🧬🧬 @lumanity @lexrovner @64xbio @jura_bio @lizbwood @AegleRxCorp

More info here:
👇👇👇
https://t.co/m3K48LR3s0

[Longevity Technology @LongevityTech]

Interviews of 2023: the longevity companies
Six of our favourite interviews with companies operating at the cutting edge of longevity science.
#biotech #innovation #2023 #longevity
https://t.co/PSwHTsS7on

[Longevity Technology @LongevityTech]

‘We’re turning aging research into a therapeutic category’
@rejuvenatebio CEO @DanielCOliver on why sourcing gene therapy targets from aging research may hold the key to treating many chronic diseases.
@geochurch #longevity #aging #genetherapy
https://t.co/ISjPtWRIS2

[ASGCT @ASGCTherapy]

How do we facilitate informed consent for approved #genetherapy + #celltherapy products?

Providers should acknowledge limits & share what they know to help patients navigate expectations, says @drjodiwolff (@rejuvenatebio). #PatientEducation https://t.co/azP5M9h15s